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qAbstract
Congenital muscular dystrophies (CMDs) are early onset disorders of muscle with histological features suggesting a dystrophic
process. The congenital muscular dystrophies as a group encompass great clinical and genetic heterogeneity so that achieving an
accurate genetic diagnosis has become increasingly challenging, even in the age of next generation sequencing. In this document we
review the diagnostic features, diﬀerential diagnostic considerations and available diagnostic tools for the various CMD subtypes and
provide a systematic guide to the use of these resources for achieving an accurate molecular diagnosis. An International Committee
on the Standard of Care for Congenital Muscular Dystrophies composed of experts on various aspects relevant to the CMDs
performed a review of the available literature as well as of the unpublished expertise represented by the members of the committee
and their contacts. This process was reﬁned by two rounds of online surveys and followed by a three-day meeting at which the
conclusions were presented and further reﬁned. The combined consensus summarized in this document allows the physician to
recognize the presence of a CMD in a child with weakness based on history, clinical examination, muscle biopsy results, and
imaging. It will be helpful in suspecting a speciﬁc CMD subtype in order to prioritize testing to arrive at a ﬁnal genetic diagnosis.
 2014 The Authors. Published by Elsevier B.V.
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The congenital muscular dystrophies (CMDs) and the
congenital myopathies (non-dystrophic myopathies with
characteristic histological and histochemical ﬁndings)
constitute the two most important groups of congenital
onset muscle disease. The CMDs are deﬁned as early
onset muscle disorders in which the muscle biopsy is
compatible with the presence of a dystrophic process
(even if not fully developed) without histological evidence
of another neuromuscular disease [1,2]. However, it has
become clear that there is overlap between the CMDs
and and the congenital myopathies on the clinical,
morphological and genetic level. For example, mutationsTable 1
Brief CMD classiﬁcation overview (underlined: abbreviated nomenclature use
Subtype and alternate nomenclatures
Associated Genes
As
Collagen VI related dystrophies (COL6-RD)
COL6A1, COL6A2, COL6A3
j
j
j
Laminina2 related dystrophy (LAMA2-RD, includes MDC1A, Merosin
deﬁcient CMD, LAMA2-CMD)
LAMA2
j
j
j
aDystroglycan related dystrophy (aDG-RD, also alpha
dystroglycanopathy, aDGpathy)
FKRP, FKTN, POMT1, POMT2, POMGnT1, LARGE, ISPD,
GTDC2, DAG1,TMEM5, B3GALNT2, B3GNT1, GMPPB, SGK196
(DPM1, DPM2, DPM3, DOLK)
j
j
j
j
j
j
j
SEPN1 related myopathy (SEPN1-RM, also rigid spine CMD, RSMD1)
SEPN1
j
j
RYR1 related myopathy (RYR1-RM, includes RYR1-CMD)
RYR1
j
j
LMNA related dystrophy (LMNA-RD, includes LMNA-CMD, L-
CMD, and Emery Dreifuss)
LMNA
j
j
CMD without genetic diagnosis jin RYR1 and SEPN1 can cause both core disorders
(belonging to the congenital myopathies) as well as
CMD-like presentations. The clinical as well as genetic
complexity of the disorders subsumed under the CMDs
has resulted in diﬀerent genetic as well as clinical
classiﬁcation schemes [3–5]. Also, the genetic
nomenclature used is not always consistent. For instance
MDC1A (muscular dystrophy, congenital, type 1A) refers
to disease caused by mutations in LAMA2, but this
nomenclature system has not been systematically carried
forward for all CMDs. Table 1 lists most currently used
names and symbols for reference. Gene symbols in this
review are not italicized. We have used the gene or
protein name annotated by “–related dystrophy (–RD)”d in this paper).
sociated phenotypic spectrum
Ullrich congenital muscular dystrophy (UCMD) – severe nonambulant
and transient ambulant
Intermediate phenotype
Bethlem myopathy (BM, milder disease course)
Non-ambulant LAMA2-RD
Ambulant LAMA2-RD
Non-ambulant typically correlates with absent laminin a2 staining on
muscle biopsy and ambulant with partial deﬁciency (with exeptions)
Walker–Warburg syndrome
Muscle–eye–brain disease; Fukuyama CMD; Fukuyama-like CMD
CMD with cerebellar involvement; cerebellar abnormalities may include
cysts, hypoplasia, and dysplasia
CMD with mental retardation and a structurally normal brain on
imaging; this category includes patients with isolated microcephaly or
minor white matter changes evident on MRI
CMD with no mental retardation; no evidence of abnormal cognitive
development
Limb-girdle muscular dystrophy (LGMD) with mental retardation
(milder weakness, maybe later onset) and a structurally normal brain
on imaging
LGMD without mental retardation (milder weakness, maybe later onset)
Consistent rigid spine early respiratory failure phenotype
despite variable histological presentations as multiminicore disease,
desmin positive Mallory body inclusions, congenital ﬁber-type
disproportion, mild CMD, or nonspeciﬁc myopathy
RYR1 related myopathies (RYR1-RM) include central core, multi-mini-
core, centronuclear and nonspeciﬁc pathologies. which can assume CMD
like characteristics
Clinically signiﬁcant for early scoliosis and absent or limited ambulation
CMD presentation: Dropped head syndrome, axial and scapuloperoneal
involvement, absent or early loss of ambulation
Milder presentations fuse with early-onset Emery–Dreifuss muscular
dystrophy
Congenital onset weakness with CMD compatible histology and variable
clinical features, without conﬁrmed genetic diagnosis, despite testing for
currently known genes
Fig. 1. A–D: Diﬀerential diagnostic considerations for various clinical ﬁndings in infancy (A) and beyond infancy (B and C), as well as for various
laboratory ﬁndings that may be available at the outset of the diagnostic encounter (D). Note: The most important tools in the clinical diﬀerential diagnosis
are: EMG/NCV to diagnose neurogenic involvement, muscle biopsy, and selective biochemical and genetic testing. The diﬀerential diagnostic
considerations are not exhaustive but highlight a few of the more relevant conditions to consider with a given clinical picture. To save space we are only
using the gene/protein symbols to indicate speciﬁc diagnosis.
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phenotypic classes to reﬂect the type of pathology that is
more typically encountered in a biopsy for the subtypewhile allowing for a broad phenotypic and
histopathological spectrum associated with the respective
primary gene. If we are referring speciﬁcally to the
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presentations we use “–related CMD”. Myopathy here is
meant to reﬂect a pathology without clear evidence of
degeneration and regeneration in the majority of cases,
although such features may be evident in some cases. The
conditions designated as “related myopathy” are also
those that may have presentations as more typical
congenital myopathies.
The incidence and prevalence of CMD in various
populations is not suﬃciently known and may have been
underestimated in early published CMD surveys owing to
more limited diagnostic means available. Point prevalence
in early studies ranges from 0.68 to 2.5 per 100,000 [6–9].
The relative frequency of individual types also varies in
diﬀerent populations. In Japan, the most commonly
diagnosed CMD subtype is Fukuyama CMD caused by a
founder mutation in the fukutin gene, followed by
COL6-RD [10], while fukutin mutations are very rare in
other populations [11,12].
Individual CMD forms are rare so that only highly
specialized centers have the combined diagnostic
experience and technology to cover all subtypes. It thus
frequently falls on the primary pediatric, neuromuscular
provider or pathologist caring for a patient with
suspected CMD to coordinate and interpret data and
results from diﬀerent disciplines and laboratories in an
eﬀort to achieve a diagnosis for an individual patient.
Establishing a molecular diagnosis however is of
importance for genetic and prenatal counseling, prognosis
and anticipatory management, and also for future
stratiﬁcation for clinical trials and treatment approaches
that are speciﬁc for an individual subtype or even are
mutation-speciﬁc. In an eﬀort to arrive at consensus
guidelines for achieving a speciﬁc genetic diagnosis in an
individual patient, an international group involving the
majority of experts in the ﬁeld have participated in
working groups and meetings to summarize currently
available data and literature, unpublished experience, and
individual expertise to develop a rational and
comprehensive approach to the speciﬁc diagnosis of the
heterogeneous disorders currently subsumed under CMD.
2. General clinical ﬁndings in the congenital muscular
dystrophies
(See diagnostic schematics “On Presentation, Fig.
1A–C”.)
Initial presentation and its diﬀerential diagnosis: When
presenting in infancy there are certain clinical signs that
point towards or are compatible with a CMD diagnosis,
while other presenting features make a diagnosis of CMD
much less likely (speciﬁc clinical ﬁndings will be discussed
under diagnostic aspects of the CMD subtypes below).
The most important diﬀerential diagnostic considerations
for the hypotonic and weak infant outside of CMD (and
excluding systemic metabolic and acquired conditions)
are the congenital myopathies, congenital myasthenicsyndromes, congenital metabolic myopathies, very early
SMA and amongst the non-neuromuscular genetic
conditions in particular Prader–Willi syndrome. Fig. 1A
contains a diagnostic schematic for infants <2–3 years
starting with clinical ﬁndings and linking them to the
diagnostic subtype considerations within the CMD and
also to diﬀerential diagnostic considerations outside of
CMD.
Presentation at an older age and its diﬀerential diagnosis:
It is not infrequent that a patient may present for diagnosis
at an older age either because a deﬁnitive CMD diagnosis
has not yet been established despite congenital onset or
because symptom onset or symptom recognition had
been delayed. Several clinical clues help to arrive at a
clinical and ﬁnally a molecular diagnosis. Fig. 1 B and C
cover clinical ﬁndings in the older child and adult,
similarly starting from clinical observations such as the
distribution of weakness and linking them to diagnostic
subtype considerations as well as to diﬀerential diagnostic
considerations outside of CMD.
Initial testing available: CK levels can be normal in
SEPN1-RM and is often normal or only mildly elevated
in COL6-RD, however, it is consistently elevated in
LAMA2-RD and elevated most of the time (but not in
100% of patients) in aDG-RD. Brain MRI can help
support the clinical diagnosis in the aDG-RD and
LAMA2-RD (see below). While EMG/nerve conduction
testing ﬁndings are not diagnostic in CMD they often
show myopathic features (in LAMA2-RD they
commonly also show peripheral motor and sensory
neuropathy of lower extremities [13–15]). A typical
decremental response on repetitive stimulation is not
compatible with a CMD diagnosis and should suggest a
congenital myasthenic syndrome.
3. Diagnostic aspects of speciﬁc subtypes
3.1. LAMA2-CMD-RD (Laminin a 2 related CMD,
Merosin deﬁcient CMD, MDC1A)
Diagnostic considerations: Laminin a2 related CMD is
caused by mutations in the LAMA2 gene, encoding the
a2 heavy chain of the laminin 211 isoform (a 2/b1/c1),
also known as merosin [16–19]. In the genetic
nomenclature, this CMD subtype is also referred to as
MDC1A. Complete absence of laminin a2 staining on
muscle (or skin biopsy) is more common and in general
associated with a more severe non-ambulatory
phenotype compared to a partial laminin a2 deﬁciency
[20]. Patients (Fig. 2G, F) with complete laminin a2
deﬁciency present at birth with signiﬁcant hypotonia
and weakness of the extremities, which may worsen in
the ﬁrst few weeks of life in some infants. There may be
contractures in the hands and feet at birth
(arthrogryposis). In patients with complete deﬁciency the
degree of muscle weakness usually precludes
independent ambulation, although patients may get to a
Fig. 2. A: Hand of a patient with COL6-RD. Note the signiﬁcant hyperlaxity even in the most distal interphalangeal joints. B: Foot of an infant with
COL6-RD. Note the ability to dorsiﬂex the foot back to the shin, the soft palmar skin, the pes planus (loss of arch) and the prominent calcaneus. C: Patient
with COL6-RD. Note ﬂexible ﬁngers and round face with facial erythema. He also has contractures in the elbows and knees. D: Patient with LMNA-CMD.
Note the dropped head, hyperlordosis and adducted foot indicative of peroneal weakness, and overall thinness. E: Patient with SEPN1-RM, note atrophy of
inner thigh muscles and lateral deviation of spine (status after surgical rod placement). F: Twins with LAMA2-CMD. Note hypotonic posture with splayed
legs (“frog leg” posture), weak arms, ﬂexed ﬁngers and foot contractures. G: Patient with LAMA2-CMD. Note facial weakness and foot contracture. She
has no antigravity strength in the upper extremity. H: Patient with aDG-RD (POMT1). Note weak sitting posture, hypotonic lower face with open mouth
characteristic of congenital myopathic disorders. I: Same patient with aDG-RD (POMT1) at an older age, note calf and quadriceps hypertrophy and mild
forearm hypertrophy.
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ambulation (2/33 patients in one series) [20]. Partial
laminin a2 deﬁciency due to mutations in LAMA2
tends to present with milder and more variable
phenotypes, including LGMD-like proximal weakness,
and an Emery–Dreifuss like contracture phenotype,
although manifestations may also be as severe as in the
complete deﬁcient patient [10,20–23]. In LAMA2-RD,
particularly in the ﬁrst 2 years of life, the CK is
typically elevated more than ﬁve times normal. Typicalﬁndings on brain MRI (Fig. 3A, B) include high signal
in the white matter on T2 weighted and FLAIR images
and are seen in all patients but are most obvious in
patients greater than 6 months of age. The internal
capsule, corpus callosum, and other dense ﬁber tracts
are usually spared, but there may be subcortical cyst
formation. White matter changes once evident do not
require further imaging. White matter abnormalities on
MRI are also seen in patients with incomplete
deﬁciency, while patients with very late adulthood onset
Fig. 3. A and B: T2-weighted brain MR images in LAMA2-CMD. Note extensive signal abnormalities of the cerebral white matter while the corpus
callosum and the internal capsule are spared (arrows). C: T1 weighted brain MRI in aDG-RD (POMT2).Note thinning of the corpus callosum, the
relatively ﬂat pons (arrow) and atrophic and dysplastic cerebellar vermis (arrow head). D and E: T2-weighted MR images in aDG-RD. Note thin corpus
callosum, extremely small pons, relatively thick tectum (arrow head), and small and dysplastic cerebellar vermis on the sagittal cut (D). Frontal
polymicrogyria (arrow) and abnormal white matter signal is evident on the axial cut (E). F: T1-weighted MR images in aDG-RD. Note abnormal
conﬁguration of the pons and corticospinal tracts and dysplastic cerebellum with cerebellar cysts (arrow) and small vermis (arrow head)). G: T1-TSE
weighted thigh MR images in a COL6-RD, a patient with typical phenotypic UCMD presentation. Note in particular the striated aspect of vastus lateralis
caused by outer rim of increased signal (arrow) and increased signal around the central fascia of the rectus femoris (arrow head) (courtesy of Dr. R
Carlier). H: T1-TSE weighted thigh MR images in SEPN1-RM. Note selective involvement of sartorius (arrow), biceps femoris and adductor magnus and
sparing of the gracilis (arrow head).
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5%) of patients shows more obvious brain structural
abnormalities, including a particular occipital cortical
dysgenesis with a subcortical band of heterotopia and
cerebellar hypoplasia [24]. Seizures occur in about 30%
of all patients with LAMA2-RD, including in those
with no obvious evidence for a cortical malformation on
imaging.
Selected genotype–phenotype correlations: Most
mutations resulting in typical complete laminin a2
deﬁciency are functionally null mutations leading to the
absence of the laminin a2 protein on immunostaining
and a more severe non-ambulatory phenotype. 55% of
mutations in one series were located in exons 14, 25, 26,
27 [20]. Compound heterozygosity for a null mutation
and an in-frame deletion or exon skipping mutations may
lead to a milder phenotype with partial deﬁciency of
laminin a2 [10]. In contrast, in-frame deletions aﬀecting the
N-terminal G-domain, critical for binding of laminin
isoforms to a-dystroglycan and various integrins, aﬀect
the function of this molecule profoundly, leading to a
severe phenotype, even though laminin a2 may be
partially present in the basement membrane by
immunohistological exam [25]. Rare homozygous
missense mutations have been associated with laminin a2
deﬁciency [20]. Aﬀected siblings may demonstrate
intra-familial variability for onset and severity of clinical
manifestations and degree of laminin a2 deﬁciency noted
on muscle biopsy immunostaining.
3.2. Alpha dystroglycan related dystrophies (aDG-RD)
Diagnostic considerations: The aDG-RDs, are
characterized by reduced O-mannosyl and
LARGE-dependent glycosylation of a-dystroglycan, a
sarcolemmal membrane structural protein. This is the
result of mutations in the currently 13 genes directly or
putatively involved in the glycosylation pathway
(POMT1, POMT2, POMGnT1, FKRP, Fukutin,
LARGE, ISPD, GTDC2, B3GALNT2, B3GNT1,
TMEM5, GMPPB, SGK196) [26,27]. A single mutation
in dystroglycan (DAG1) that speciﬁcally interferes
with its glycosylation can lead to an aDG-RD [28].
Mutations in the dolichyl-phosphate mannosyltransferase
subunit genes DPM1, DPM2 and DPM3 cause
overlap syndromes of muscular dystrophy with
under-glycosylated aDG in the muscle [29–31], while
mutations in the dolichol kinase DOLK are a cause of
dilated cardiomyopathy [32]. aDG-RD classiﬁcations
have been proposed to accommodate the very broad
clinical spectrum, ranging from syndromic CMD forms
with very severe brain involvement (including WWS,
FCMD and Muscle-Eye-Brain disease) to the LGMD
spectrum [5,33–42]. It may be diﬃcult to unequivocally
classify patients with transitional milder CNS
abnormalities including microcephaly, cerebellar
hypoplasia with or without cysts or patients with learningdisability with normal appearing MRI presenting with
either CMD or LGMD like age of symptom onset with
or without achieved ambulation as it may be diﬃcult to
assign a delay in acquisition of motor milestones to the
global developmental delay as opposed to muscle
weakness. Normal cognitive abilities have been
encountered in patients with FKRP, FKTN, and ISPD
mutations while cognitive impairment which ranges from
profound mental retardation to mild learning disability
has been observed in patients with mutations in all 17
genes (DAG1, POMT1, POMT2, POMGnT1, LARGE,
FKRP, FKTN, ISPD, GTDC2, B3GNT1, B3GALNT2,
GMPPB, TMEM5, SGK196, DPM1, DPM2, DPM3).
In the aDG-RDs, the spectrum of the muscle
involvement is broad for all subtypes, ranging from
prenatal onset weakness precluding ambulation, to
Duchenne and Becker-like severities (Fig. 2H, I). The
distribution of muscle weakness is proximal with a
tendency for muscle hypertrophy and pseudohypertrophy
in both upper and lower extremities. Scapular winging,
lumbar lordosis and a Trendelenburg gait can be present.
Some patients have experienced myositis-like rapid decline
in function that was partially responsive to steroid
treatment [43–45]. Dilated cardiomyopathy is most
commonly found in aDG patients due to FKRP and
FKTN mutations, especially in those patients at the
LGMD end of the clinical spectrum, and less commonly
in POMT1 mutations. However, echocardiographic
surveillance has to be considered in any
dystroglycanopathy patient [46,47]. The hallmark of
central nervous system involvement in the aDG-RD on
brain MRI (Fig. 3C-F) is represented by the cobblestone
complex, ranging from complete lissencephaly (type II) to
more focal pachygyria or polymicrogyria showing a
frontal predominance. Similar to LAMA2-RD there may
also be an occipital cortical dysplasia with a smooth
appearing cortex and an underlying heterotopic band of
neurons. Characteristic infratentorial ﬁndings may include
midbrain hypoplasia, a relatively thick tectum, fused
colliculi, a pontomesencephalic kink, ventral pontine cleft,
pontocerebellar hypoplasia, abnormalities of cerebellar
foliation and cerebellar cysts, which are frequently
observed in POMGnT1, and FKRP mutations and have
recently been described in POMT2 and LARGE patients
[48,49]. Some patients may only have frontal
polymicrogyria without infratentorial involvement (seen in
POMT1, POMT2 and LARGE), while some may only
have infratentorial involvement (ISPD) [50]. MRI
ﬁndings may also include hydrocephalus, and occipital
encephalocele. There may be high signal in the white
matter on FLAIR or T2-weighted images showing
patchy or more conﬂuent involvement. In contrast to
LAMA2-RD, these white matter abnormalities can regress
over time [48,51,52], and are not typically observed in
dystroglycanopathy patients with preserved intelligence.
Selected genotype–phenotype correlations: The number of
aDG-RD diagnosis without a mutation in one of the
C.G. Bo¨nnemann et al. / Neuromuscular Disorders 24 (2014) 289–311 297currently known genes is not entirely clear, but it is still
signiﬁcant and additional genes will likely be found.
While point mutations are the most common mutation
type in all genes, genomic deletions or deletion-insertions
have been reported in particular POMT2 and LARGE
[49,53,54]. Mutations in POMGnT1 showed the highest
correlation with the typical MEB phenotype [38,55].
Patients homozygous for the ancestral Japanese mutation
(insertion of a retrotransposon) in FKTN have a
comparatively milder phenotype (FCMD), while the
disease severity increases towards the MEB and WWS
range in patients who are compound heterozygous for this
ancestral mutation and a more severe loss-of-function
mutation on the other allele [56]. Homozygous null
mutations in the human FKTN gene have resulted in a
WWS-like phenotype [57]. FKRP, FKTN and ISPD
mutations are associated with the broadest clinical
spectrum to date ranging from WWS to a Becker-like
limb girdle muscular dystrophy [51,58,50,59]. The
c.826C>A (p.Leu276Ile) mutation in the FKRP gene is
particularly common in LGMD2I patients, but can be
associated with a more severe phenotype in the compound
heterozygous state depending on second mutation [37,58].
In contrast, most of the CMD associated FKRP mutations
are unique to individual patients. In the POMT1 and
POMT2 genes, mutations leading to severe functional
defects appear to be associated with severe WWS or MEB
phenotypes [53], whereas less disruptive missense changes
result in milder phenotypes such as CMD or even LGMD
with mental retardation and normal MRI [41,60–62].
New genes associated with alphaDG-RD are
continuously added reducing the percentage of patients in
the alphaDG spectrum without genetic basis: Recessive
mutations in the ISDP (isoprenoid synthase domain
containing protein) have recently been identiﬁed as a
novel cause for WWS [63,64], but ranging to the milder
spectrum with isolated cerebellar involvement and
LGMD like presentations without cognitive involvement
[50]. Mutations in CTDC2 were found in consanguineous
WWS families [65], while TMEM5 mutations have been
identiﬁed in aborted fetuses with severe cobblestone
lissencephaly typical of aDGpathy [66] and in WWS and
MEB [67]. b-1,3-N-acetylgalactosaminyltransferase 2
(B3GALNT2) mutations were shown to cause CMD with
brain and eye abnormalities consistent with the alpha
DG-RD spectrum [68], while mutations in GDP-mannose
pyrophosphorylase B (GMPPB) were associated with a
spectrum from severe CMD with brain involvement to
milder LGMD [69], and SGK196 mutations in one
family with WWS [67].
The congenital disorders of glycosylation associated with
mutations in the DPM1, DPM2 and DPM3 [29–31] while
showing reduced alpha-dystroglycan and elevated CK,
also present with cognitive impairment, microcephaly,
cerebellar hypoplasia, feeding diﬃculties and notably
severe myoclonic epilepsy. Recessive mutations in DOLK
so far present mostly as a dilated cardiomyopathy [32].3.3. Collagen VI related dystrophies (COL6-RD)
Diagnostic considerations: Collagen VI is an important
component of the muscle extracellular matrix where it
interacts with the basement membrane of all muscle
ﬁbers. Mutations in one of the three collagen 6 alpha
genes (COL6A1, COL6A2, COL6A3) can have recessive
as well as dominant modes of action and inheritance
patterns, leading to the COL6-RD spectrum, ranging
from early onset, severe Ullrich CMD (UCMD) to an
intermediate severity phenotype to milder Bethlem
myopathy (BM). (For reviews see [70–73].)
UCMD (Fig. 2A-C) typically presents in the newborn
period with striking distal joint hypermobility of the
hands and often feet with prominent calcanei, while
talipes equinovarus can also occur [1]. Congenital hip
dislocation is frequently present. Proximal elbow and
knee contractures, kyphoscoliosis, and torticollis may be
also present at birth and may improve initially with
physical therapy and orthopaedic treatment. Later in life,
joint contractures return and progress, in particular in
the long ﬁnger ﬂexors, shoulders, elbows, knees and hips,
and spine becomes stiﬀ with risk of kyphoscoliosis. While
some UCMD patients may not achieve the ability to
walk, more commonly walking is achieved for some
years, and then is lost again in the late ﬁrst or early
second decade of life due to combined progressive hip
contractures and increasing weakness. A steady decline in
percent predicted forced vital capacity is observed in
virtually all Ullrich patients, leading to predominantly
night-time respiratory insuﬃciency [74–76] in which the
diaphragm is disproportionally aﬀected [77,78].
In the allelic Bethlem phenotype onset may either be as
early as the congenital period but with few conspicuous
ﬁndings in early childhood such as mild weakness and
some degree of joint hypermobility, or clinical
recognition may be later. Contractures of the Achilles
tendons, pectoralis muscle, elbows and long ﬁnger ﬂexors
develop progressively. The weakness itself is slowly
progressive. Respiratory compromise is also less
conspicuous in the Bethlem phenotype, although
weakness may progress in adulthood [74,79]. Clinical
phenotypes that are intermediate between these two
classic presentations include patients with early
presentation who are ambulating to late teenage years or
young adulthood but still presenting progressive
respiratory failure, even while still ambulating [76,78,80],
Characteristic skin ﬁndings are diagnostically helpful and
include a tendency for keloid or atrophic scar formation,
striae, soft velvety skin on palms and soles and
hyperkerotosis pilaris [81]. Cognition is normal and often
advanced for age. CK is normal or mildly elevated.
Diﬀerential diagnostic considerations for milder
COL6-RD phenotypes with prominent joint contractures
include LAMA2-RD with partial deﬁciency, LMNA-RD
as well as other Emery–Dreifuss muscular dystrophies. In
contrast to LMNA-RD and Emery–Dreifuss muscular
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not develop cardiac involvement. For patients with
very prominent joint hypermobility, the relevant
diﬀerential diagnostic considerations are kyphoscoliotic
Ehlers–Danlos syndromes (type VI) and the hypermobile
type caused by mutations in tenascin X [82]. Recently
recognized EDS/myopathy overlap syndromes to consider
in the diﬀerential diagnosis include a form with severe
kyphoscoliosis and myopathy due to FKBP14 mutations
[83] and forms due to mutations in collagen XII ranging
from severe and precluding ambulation to milder
presentations [84,85]. Analysis of collagen VI in dermal
ﬁbroblast cultures may add sensitivity to the biochemical
testing [73,86–88]. The availability of ﬁbroblast cultures
also allows for genetic testing and conﬁrmation of splice
mutations on ﬁbroblast derived cDNA. This type of
analysis is currently only available in research laboratories
and is often needed to conﬁrm a molecular diagnosis given
the important role of splice mutations.
Selective genotype–phenotype correlations: Even though
two new collagen VI related genes have been identiﬁed in
humans (COL6A5 and COL6A6 [89,90]), all cases of
COL6-RD identiﬁed to date are related to mutations in
the original COL6A1-3 genes with genotype–phenotype
correlations established in larger published cohorts of
similar mutations [11,21,73,91,92]. Mutations underlying
the severe end of the spectrum are typically recessive loss
of function mutations that prevent any chains from
assembling [21], occasional recessive missense mutations
[93], and importantly de novo dominant negative
mutations [21,92]. Dominant negatively acting mutations
are usually in-frame exon skipping mutations or glycine
missense mutations of the collagenous Gly-X-Y motif at
the N-terminal end of the triple helical domain, allowing
them to be carried forward in the assembly
[21,91,92,94,95]. Bethlem myopathy is typically caused
dominantly acting mutations with less severe functional
impact, [91,94], while recessive mutations are less
common [96,97]. In particular dominantly acting glycine
missense mutations are associated with a phenotypic
range that extends from typical Ullrich CMD to Bethlem,
and are also responsible for large number of patients in
the intermediate severity group discussed earlier [73,91].
Large exonic or even the whole gene deletions that will
not be recognized by exon sequencing based testing can
occur in COL6A1 and COL6A2 in particular [98,99].
3.4. SEPN1 related myopathy (SEPN1-RM)
Diagnostic considerations: SEPN1-RM is a congenital
muscle disorder caused by autosomal recessive mutations
of the SEPN1 gene, which encodes selenoprotein N
(SelN) and plays a key role in protecting human cells
against oxidative stress [100,101]. Poor or delayed head
control in the ﬁrst months of life is the most common
presenting sign, although almost all patients continue toacquire motor milestones and achieve independent
ambulation often at a normal age. Neonatal respiratory
failure, severe feeding diﬃculties, congenital contractures
or major joint hyperlaxity would be highly unusual
presenting features. During later infancy and childhood,
muscle weakness and slenderness remain more marked in
axial groups, particularly in neck ﬂexors and sometimes
extensors (dropped head) [102–104]. In contrast, limb
strength and therefore walking ability are usually
preserved, although diﬃculties climbing stairs, walking
long distances and easy fatiguability are common.
Marked progression has been observed in several cases
after the fourth decade. Other characteristic features are
a relative atrophy of the inner thigh muscles, mild
hyperlaxity of hands and wrists and mild facial weakness
with a typical nasal voice. Mild ophthalmoparesis is
uncommon but can be seen particularly in severe cases.
In a series of patients with hirsutism, signs of insulin
resistance were detected [105]. Joint contractures are
absent or mild but they are severe in the spine leading to
a spinal stiﬀness which may appear around 5–6 years of
life or even earlier. Later on, thoracic lordoscoliosis with
lateral translation is a frequent complication (Fig. 2E).
Progressive restrictive respiratory failure frequently
manifests by the end of the ﬁrst decade of life as
nocturnal hypoventilation even in children with fairly
preserved vital capacity. As in Ullrich patients,
diaphragmatic failure may be observed and most patients
require non-invasive ventilation while still ambulant, at
an average age of 13.9 years with a range of 1 to
33 years, suggesting that respiratory surveillance should
be initiated at diagnosis [104]. CK is normal or mildly
elevated (less than 4-fold).
SEPN1-RM needs to be diﬀerentiated from other
conditions with prominent spinal rigidity, particularly
Emery–Dreifuss muscular dystrophy, FHL1 related
myopathies, Pompe disease, COL6-RD (UCMD, Bethlem
myopathy), and some cases of RYR1 related core disease.
Joint contractures are not typical of SEPN1 and this is a
diﬀerential feature with most of these entities, but this
complication may not be present at young ages. Drop head
and spinal rigidity are also observed in LMNA-RD, but
CK levels are usually higher in LMNA-RD and muscle
weakness distribution in the limbs is diﬀerent (proximal in
upper extremities and distal in lower limbs in LMNA-RD).
Selective genotype–phenotype correlations: Mutations
are distributed along the whole gene, except exon 3 and
the majority are nonsense mutations, microdeletions or
insertions leading to frameshifts, as well as splice-site
mutations leading to aberrant pre-mRNA splicing
(reviewed in Lescure et al., [106]) [100,104,99].
Interestingly, several mutations aﬀect the cis sequences (30
UTR SECIS element, Sec codon redeﬁnition element
(SRE)) required for selenocysteine insertion which needs
to be evaluated if Sanger sequencing of coding exons
does not reveal a mutation [107–109].
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presenting as CMD (RYR1-CMD)
Patients with recessive mutations in the RYR1 gene
coding for the sarcoplasmic reticulum calcium release
channel may present with a distinct CMD like
presentation (RYR1-CMD) which falls into the larger
context of recessive RYR1-RM that now includes
centronuclear (CNM), central core, multi-minicore, and
ﬁber type disproportion histological presentations
[110,111]. RYR1-CMD lacks evidence for typical core
formation on muscle biopsy staining with NADH and
other oxidative stains, but presents with a histological
and clinical picture most suggestive of CMD. Like
SEPN1 mutations, RYR1 mutations can present as
disorders sharing features of both a congenital myopathy
and a CMD. There is evidence to suggest common
aspects to the pathogenesis in both of these disorders and
that they may physically interact [101]. Clinically,
patients with RYR1-CMD may present with signiﬁcant
congenital onset hypotonia, including facial weakness and
early onset severely progressive scoliosis. Nocturnal
ventilatory support due to pulmonary insuﬃciency and
gastrostomy due to feeding and swallowing diﬃculties
may be required. Although not frequent, CK can be
mildly elevated. Ophthalmoplegia/paresis as seen in the
the centronuclear and multi-minicore presentations of
recessive RYR1 mutations may be absent in the CMD
like presentation of RYR1-CMD.
3.6. LMNA related CMD (LMNA-CMD)
Mutations in the lamin A/C (LMNA) gene, cause a wide
range of genetic disorders in humans, including muscular
dystrophies (LMNA-RD) [112,113]. The typical
neuromuscular disorder associated with lamin A/C
mutations is Emery-Dreifuss muscular dystrophy
(EDMD), characterized by scapuloperoneal muscle
weakness, contractures of elbows, heel cords and spine,
scoliosis, cardiomyopathy and cardiac arrhythmias. More
recently mutations in LMNA have also been identiﬁed in
patients with an early onset CMD form (LMNA-CMD)
[114,115].
In LMNA-CMD, weakness becomes evident in infancy,
sometimes including a brief phase of more rapid
progression during the ﬁrst 24 months of age with loss of
early motor milestones. Characteristic weakness of axial
and neck muscles (ﬂexors and extensors) causes the
clinical phenomenon of head-drop or “dropped head
syndrome” (Fig. 2D) [115–117], due to very weak neck
extensors. In addition there is pronounced lumbar
hyperlordosis at a very early age, arm and hand
weakness as well as peroneal predominant weakness
while hip ﬂexors are better preserved demonstrating good
antigravity strength. Thus, weakness resembles an early
axial–scapulo–peroneal pattern in addition to the early
and severe axial weakness. Contractures manifest in theAchilles tendon, knees, hips and spine with considerable
spinal rigidity, with less contractures in the elbows and
ﬁnger ﬂexors or extensors when compared to classic
Emery–Dreifuss phenotype and COL6-RD. In the most
severe cases, sitting and head support may never be
achieved. More commonly, walking ability is acquired
but it is lost later in life, often after a short period of
time. Night-time respiratory insuﬃciency with
hypoventilation and hypercapnea may manifest early
[115]. Similar to Emery–Dreifuss phenotype, cardiac
involvement in LMNA-CMD may take the form of an
initially atrial arrhythmogenic cardiomyopathy with
conduction block, and also ventricular tachyarrhythmias,
necessitating the use of an AICD. Cognition is
unaﬀected. CK levels can be mildly to moderately
elevated. The most important diﬀerential diagnostic
consideration is SEPN1-RM (see section 3.4.).
Selective genotype–phenotype correlations: All identiﬁed
mutations so far have been heterozygous de novo
mutations that act in a dominant negative way [114].
Some mutations seem unique to LMNA-CMD, while
other mutations also occur in patients at the severe end
of the spectrum of the Emery–Dreifuss phenotype
[115,118].
3.7. Mutations in metabolic pathway genes presenting as
CMD
Several genetic causes for CMD like presentations have
been described recently and involve mutations in genes that
are involved in metabolic pathways (see Table 2).
CHKB-related CMD: Mutations in choline kinase B,
which is involved in phosphatidylcholine biosynthesis,
cause a congenital onset muscular dystrophy with large
appearing mitochondria (megacolonial or giant
mitochondria) on oxidative stains and ultrastructure
[119]. Aﬀected patients in addition show cognitive
impairment but normal brain MRI ﬁndings and also skin
ﬁndings including acanthosis nigricans like lesions with
intense pruritus. This clinical constellation together with
the biopsy ﬁndings is diagnostic [2].
3.8. Paraclinical Diagnosis of CMD
3.8.1. Muscle pathology
The careful evaluation of the muscle biopsy often is
essential to suggest or support a genetic diagnosis. Proper
performance, handling, and processing of the biopsy
specimen need to be assured [120]. The muscle biopsy
should be obtained from a skeletal muscle that is
clinically aﬀected but not to a degree that makes it
unsuitable for diagnosis due to near complete
replacement of muscle by connective and fatty tissue.
Although the degree of involvement of the muscle can be
suspected on clinical grounds, it may be very helpful to
utilize muscle imaging (MRI, ultrasound, or CT) to
estimate the degree of involvement. It is important to
Table 2
Summary of currently recognized Congenital Muscular Dystrophies.
Disease entity Protein product
Gene symbol
Salient clinical features CNS imaging ﬁndings Immuno-histochemical
diagnosis
Laminin alpha 2 related CMD (primary merosin/laminin2 deﬁciency)
CMD with
primary
laminin-211
(merosin)
deﬁciency
(MDC1A)
Laminin-a2
LAMA2
Complete deﬁciency: Maximal
motor ability is sitting and standing
with support. Milder (contractural)
presentations with partial
deﬁciency. Generally normal mental
development, epilepsy in about 30%,
Abnormal white matter signal (T2
weighted MRI), 5% occipital
pachy- or agyria, pontocerebellar
atrophy (rare)
Complete or partial
deﬁciency for laminin a2
Alpha-dystroglycan related Dystrophies
CMD with
partial
merosin
deﬁciency
(MDC1B)
Not known
(locus: 1q42)
Variable severity, delayed onset
possible, proximal limb girdle
weakness, muscle hypertrophy,
early respiratory failure possible.
Abnormal white matter and
structural grey matter changes
possible. Expanding spectrum.
Variable deﬁciency of the
glycosylated aDG epitope,
secondary reduction of
laminin211
LARGE related
CMD
(MDC1D)
LARGE Variable. CMD with signiﬁcant
mental retardation, may eventually
blend with the MEB/WWS
spectrum.
White matter changes, mild
pachygyria, hypoplastic
brainstem, cerebellar
abnormalities incl cysts.
Same
Fukuyama CMD
(FCMD)
Fukutin
FCMD
Frequent in the Japanese
population, walking not achieved,
mental retardation, epilepsy
common, more limited eye ﬁndings
but clinical overlap with MEB.
Lissencephaly type II/pachygyria,
hypoplastic brainstem cerebellar
abnormalities, including cysts.
Same
Muscle-eye-brain
disease
(MEB)
POMGnT1
FKRP, Fukutin, ISPD,
TMEM5
Signiﬁcant congenital weakness,
walking is rarely achieved, motor
deterioration because of spasticity.
Mental retardation, signiﬁcant
ocular involvement (e.g. severe
myopia, retinal hypoplasia).
Lissencephaly type II/pachygyria,
brain stem and cerebellar
abnormalities, including cysts
Same
Walker–Warburg
syndrome
(WWS)
POMT1
POMT2, FKRP, Fukutin,
ISPD, CTDC2, TMEM5,
POMGNT1,
B3GALNT2, GMPPB,
B3GNT1, SGK 196
Often lethal within ﬁrst years of life
because of severe structural CNS
involvement. Congenital weakness
may be less apparent in the setting
of the brain involvement. Signiﬁcant
ocular involvement possible
Lissencephaly type II, pachygyria,
hydro-cephalus, occipoital
encephalocele, hypoplastic
brainstem, cerebellar atrophy.
Same
CMD/LGMD
with MR
FKRP, POMT1, POMT2,
ISPD, GMPPB
Early onset weakness but
ambulation is often achieved, or
early onset LGMD phenotype, with
mental retardation, some patients
with microcephaly.
May be normal, or show
cerebellar cysts, or mild cortical
abnormalities. Microcephaly
without any other obvious
structural changes possible.
Same
CMD/LGMD
without MR
(including
MDC1C)
FKRP, Fukutin, ISPD,
GMPPB
Early onset weakness but often
ambulation, or early onset LGMD
phenotype, without mental
retardation, may have steroid
responsive progression of weakness,
cardiomyopathy.
No Same
Congenital Disorders of Glycosylation (CDG) with abnormal alpha-dystroglycan glycosylation
CDG I (DPM3) Dolichol-Phosphate-
Mannose Synthase-3
DPM3
1 patient: CMD/LGMD with
elevated CK, cardiomyopathy and
stroke like episode, mild
developmental disability (IQ 85)
Unexplained stroke-like episode
without clear neuroimaging
correlate
Mild reduction in aDG
glycoepitope, variable
laminin 211 reduction
CDG I (DPM2) Dolichol-Phosphate-
Mannose Synthase-2
DPM2
CMD with MR and severe
myoclonic epilepsy, elevated CK
Cerebellar vermis hypolasia,
microcephaly.
Same
CDG Ie (DPM1) Dolichol-Phosphate-
Mannose Synthase-1
DPM1
Initially described as CDG Ie, now
emerging evidence of the presence of
a dystrophic myopathy with
abnormal alpha DG
Same
(continued on next page)
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Table 2 (continued)
Disease entity Protein product
Gene symbol
Salient clinical features CNS imaging ﬁndings Immuno-histochemical
diagnosis
DOLK-CDG DOLK Non-syndromic AR dilated
cardiomyopathy
Mild reduction in aDG
glycoepitope in cardiac
muscle
Collagen VI and Integrin-related CMD forms
Collagen VI
Related
Myopathies
Ullrich/
Intermediated/
Bethlem
spectrum
(UCMD)
a1/2 and a3 collagen VI
COL6A1, COL6A2,
COL6A3
Distal joint hyperextensibility,
proximal contractures, motor
abilities variable, precludes
independent ambulation in severe
cases, soft palmar skin.
No Deﬁciency of collagen VI
immunoreactivity, in
dominant cases only
apparently deﬁcient from
the basement membrane
Integrin a7 Integrin a7
ITGA7
Very rare, delayed motor
milestones, walking with 2–3 years
No Reduced (diﬃcult stain)
CMD with
hyperlaxity
(CMDH)
3p23–21 French Canadian, presenting with
weakness, proximal contractures,
distal laxity, milder compared to
UCMD with ambulation preserved
into adulthood
No Not clear yet
Intracellular and nuclear CMD forms
SEPN1 Related
Myopathy
Selenoprotein N
SEPN1
Delayed walking, predominantly
axial weakness with early
development of rigidity of the spine,
restrictive respiratory syndrome
No No diagnostic
immunohistochemical
deﬁciency
Lamin A/C
related
Dystrophy
LMNA Absent motor development in severe
cases, more typical: “dropped head”
and axial weakness/rigidity,
proximal upper and more distal
lower extremity weakness, may
show early phase of progression
No Same
RYR1 related
CMD
RYR1 (recessive) Congenital weakness and early
scoliosis, facial weakness +/
ophthalmoplegia
No Same
CHKB related
CMD
CHKB (recessive) Congenital weakness, cognitive
impairment, pruritus, giant
mitochondria in biopsy.
No Same
PTRF related
PCGLP4 with
CMD
PTRF
(recessive)
Congenital onset generalized
progressive lipodystrophy, later
rippling muscle
No Same
CMD merosin-
positive
4p16.3 Severe muscle weakness of trunk
and shoulder girdle muscles, and
mild to moderate involvement of
facial, neck and proximal limb
muscles. Normal intelligence.
No Same
CMD with
adducted
thumbs
Nesprin Rare, adducted thumbs, toe
contractures, generalized weakness,
delayed walking, ptosis, external
ophthalmoplegia, mild mental
retardation.
Mild cerebellar hypoplasia Not clear yet
CMD with
cerebellar
atrophy
Not known Delayed motor milestones, mild
intellectual impairment.
Moderate to severe cerebellar
hypoplasia, no white matter
abnormalities.
No diagnostic immuno-
histochemical deﬁciency
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materials and assure proper storage of muscle ﬁxated for
ultrastructural analysis, frozen muscle, genomic DNA
and if possible ﬁbroblast culture. When available,establishment of a myoblast culture may be useful for
future studies in unclear CMD presentations.
Correlation with the clinical picture is often required to
arrive at a correct biopsy interpretation given the
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[2,121,122], the possible variability inherent in
performance and interpretation of the commercial
antibodies used to evaluate speciﬁc protein deﬁciencies by
immunohistochemistry [123], and the lack of the speciﬁc
stains in certain CMD subtypes. One of the most
immediate uses of a muscle biopsy is to recognize or
exclude other disorders that are important in the
diﬀerential diagnosis of CMD. Lack of any
morphological changes could indicate the presence of a
central nervous system disorder causing signiﬁcant
hypotonia, and does not exclude a metabolic problem.
On the Hematoxylin and Eosin (H&E) stain, CMD is
usually characterized by abnormal variation in ﬁber size
for age without obvious grouping. The ﬁber shape may
be rounded, and there is an increase in internalized nuclei
(but not usually central nuclei as seen in the
centronuclear myopathies). RYR1-RM in particular may
have high numbers of centralized nuclei as can congenital
DM1 as an important diﬀerential diagnosis. There is a
variable increase in endomysial connective and adipose
tissue, while the width of perimysium is increased (but
note that it is wider in general in neonates) [2,124]. There
may be necrosis, which however may not be readily
apparent on H&E so that its absence does not exclude a
CMD diagnosis. The presence of basophilic ﬁbers
suggests regenerative activity, but not all basophilic ﬁbers
are regenerating ﬁbers. The analysis of neonatal and
foetal myosins might be very helpful in these cases [120].
In addition, foci of inﬂammatory cells may be present.
Other ﬁber abnormalities that may be seen occasionally
and which are still consistent with a CMD diagnosis
include various types of vacuoles (however, these are
never a prominent ﬁnding in the biopsy), whorled and/or
split ﬁbers and hyper-contracted ﬁbers (though fewer
compared to the dystrophinopathies). In neonates, the
observation of some large Wohlfart B ﬁbers is considered
normal.
In addition, the modiﬁed Go¨mo¨ri Trichrome (mGT)
stain may be helpful in recognizing other conditions such
as rods in nemaline myopathy and ragged red ﬁbers in
mitochondrial myopathy. The mGT stain also reveals the
degree and distribution of ﬁbrosis present in the biopsy.
The oxidative stains as well as ATPase stains reveal
ﬁber typing. Fiber type 1 predominance is common in
the CMDs but is not speciﬁc for any particular
diagnosis. Fiber typing can be indistinct, particularly in
neonates. In this case myosin heavy chain
immunoﬂuorescence can be helpful. Absent clear typing
is referred to as ﬁber type uniformity and could suggest
a RYR1-RM. Fibertype grouping (of both types) is not
a feature in the CMDs and suggests the presence of a
neurogenic disorder.
Cores can be diagnosed if observed on all oxidative
stains: COX, SDH and NADH-TR stains. The presence of
large and longitudinally extended cores would usually
suggest the presence of a RYR1-RM or RYR1-CMD.However, unevenness in staining is more common and
can even be seen in COL6-RM. The presence of multiple
minicores (in particular in longitudinal section) suggests
the presence of either a SEPN1-RM or RYR1-RM, but if
infrequent is not a very speciﬁc ﬁnding. Peripheral
aggregation of mitochondria sometimes resembling
lobulated ﬁbers may occur in UCMD, although true
lobulated ﬁbers are not usually a feature in children with
any neuromuscular disorder. The presence of COX
negative and/or COX negative SDH positive ﬁbers
suggest a mitochondrial cytopathy. Very large
mitochondria, in particular towards the periphery of
ﬁbers, is indicative of a phosphatidylcholine defect
(CHKB) [125]. The size of mitochondria, degree of
glycogen and lipid accumulation can vary for a variety of
reasons, including diet and type of feed in nasogastric fed
neonates. Electron microscopy is sometimes helpful to
interpret the signiﬁcance of subtle loss of oxidative stains
as it can diﬀerentiate the myoﬁbrillar abnormalities found
in myoﬁbrillar myopathies from the disruption associated
with typical core lesions.
3.8.2. Subtype speciﬁc ﬁndings
The immunohistochemical examination is of particular
importance in the pathological workup of a patient with
suspected CMD [126]. There is a basic panel of
antibodies that need to be available for comprehensive
evaluation of the biopsy (see Table 3). In the following
section we brieﬂy summarize the general and
immunohistochemical ﬁndings for the CMD forms in
which this analysis can be diagnostic:
Laminin a2 related dystrophy (LAMA2-RD): General
histology may show a particularly pronounced buildup of
ﬁbrosis and fatty replacement, as well as sometimes
prominent presence of inﬂammatory cells, along with
evidence for degeneration and regeneration. These ﬁndings
are present early. On immunostaining typically there will
be a complete absence or near absence of laminin a2
immunostaining from all muscle ﬁbers and nerves. In cases
of a partial deﬁciency, there will be a reduction on some
muscle ﬁbers while the staining on nerves may appear
normal. Partial laminin a2 deﬁciency can be seen in both
primary LAMA2-RD and aDG-RD. If the deﬁciency is
subtle, conﬁrmation with a second laminin a2 antibody to
the 300 kDa fragment (or one that behaves similar to it)
and review of the clinical presentation to determine
consistency with a diagnosis of LAMA2-RD versus
aDG-RD are required. Fibers that are deﬁcient in
laminin a2 immunostaining will show a compensatory
upregulation of laminin a5 immunoﬂuorescence [17,126].
Upregulated laminin a5 can also be seen on regenerating
ﬁbers, thus, those will have to be excluded from this
assessment. Laminin a2 immunostaining in skin from a
patient with LAMA2-RD will show absence of laminin a2
from the epidermal/dermal junction, the sensory nerves
and all other components seen in skin (e.g. sebaceous
glands). Intramuscular nerves typically will also be
Table 3
Antibodies used routinely with consideration of CMD speciﬁc ﬁndings.
Antibody Findings
Laminin a2 Absence (in muscle ﬁbers and nerves, skin biopsy can also be used) = MDC1A
Primary reduction = MDC1A, check laminin a5 (should be elevated)
Secondary reduction = suggestive of dystroglycanopathy-check 2H6 (glycosylated aDG) labeling (in LGMD2I this reduction is
seen on blots only)
Partial reduction may need antibody against 300 kDa fragment to appreciate the reduction
Laminin b1 and c1 Should be normal in all CMDs – serves as basement membrane control in laminin a2 deﬁciency
Laminin a5 There is secondary over-expression in MDC1A (note that regenerating ﬁbers have higher expression, while moderate levels may be
present in neonatal muscle biopsies)
a-Dystroglycan Immunolabeling with antibody against glycosylated aDG (such as 2H6). Absence or virtual absence of immunolabeling = seen in
severe CMD forms, including MEB, WWS, FCMD. Also seen in LG forms with Fukutin mutation.
Incomplete or mild reduction = seen with abnormal aDG glycosylation of various severity, including LGMD presentations (unclear
genotype/phenotype correlations, some will have FKRP mutations)
b-Dystroglycan Should be normal in most CMDs – serves as a control for a-dystroglycan (some mild reduction may sometimes be seen)
Marked reduction is exclusion criterion for CMD (seen in dystrophinopathies)
Collagen VI Complete absence = suggestive of recessive UCMD
Reduction from sarcolemma only, with good preservation of sarcolemma (Labeled with perlecan of collagen IV) = suggestive of
dominant UCMD, some recessive missense mutations show similar behavior.
Normal appearance does not exclude Bethlem in particular
Cultured skin ﬁbroblasts may be more sensitive for subtle changes.
Dystrophin Absence-exclusion criterion for CMD = seen in DMD
Some mild reduction – can be secondary in some dystroglycanopathies
(no genotype correlation), if more prominent, suggestive of BMD
Note that labeling with dys 2 may be non-speciﬁcally weak in some neonates (age related)
Sarcoglycans Should be normal in all of the CMDs
Reduction – exclusion criterion
Utrophin Mild to moderate elevation of immunostaining may be non-speciﬁc, seen in regenerating ﬁbers
Consistent high levels of expression: exclusion criterion, suggestive of dystrophinopathy
Myosins Co-expression of fast and slow isoforms in several ﬁbers = suggests abnormal muscle, but is non-speciﬁc
Predominance of slow ﬁbers may occur in CMD and is nonspeciﬁc
Presence of several ﬁbers with developmental/neonatal myosin- may indicate regeneration, and/or delayed development, and/or non
speciﬁc abnormality
Note: in neonates a direct correlation of myosin immunolabeling with ATPase staining is diﬃcult as the presence of neonatal myosin
(in relation to immaturity) makes many ﬁbers stain as type 2 but they may in fact react positively for slow myosin. The decline in the
number of ﬁbers with neonatal myosin in normal muscle is not known but by 3–6 months there are generally very few. The presence
of many ﬁbres with neonatal myosin at 1 yr is indicative of an abnormality
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preserved in aDG-RD.
Alpha-dystroglycanopathy related dystrophy (aDG-RD):
General histology shows dystrophic features with
degeneration, necrosis and regeneration and ﬁbrofatty
replacement that are most similar to those seen in the
dystrophinopathies and the sarcoglycanopathies. In
contrast to LAMA2-CMD in neonatal or very early
biopsies dystrophic features may be subtle.
Immunohistochemical ﬁndings on muscle biopsy in the
aDG-RD are similar irrespective of the primary gene
involved. The degree of deﬁciency can be variable and does
not necessarily correlate with the severity of the clinical
phenotype. It is important to utilize an antibody raised
against the glycosylated form of a-dystroglycan and not
against the core protein. This glycoepitope-sensitive
antibody will show absence, near absence, or reduced
labeling on most or some of the ﬁbers. In less pronounced
cases, there may just be uneven labeling on some ﬁbers, in
which case it may be diﬃcult to clearly recognize theﬁndings as a primary deﬁciency. Western-blot analysis for
glycosylated a-dystroglycan may be helpful by showing a
reduction as well as a downward shift of the broad band of
glycosylated a-dystroglycan. Normal labeling of
b-dystroglycan on all ﬁbers will help recognize a secondary
a-dystroglycan deﬁciency seen in the dystrophinopathies
(DMD, BMD). Commercially available antibodies to
glycosylated a-dystroglycan have to be validated carefully
by comparing established disease controls with normal
samples as they may produce variable results. Laminin a2
reduction (with preservation of laminin b1, c1) will be seen
as a secondary change in primary a-dystroglycan
deﬁciency (aDG-RD). As degeneration and regeneration is
seen early on in this group of conditions, several ﬁbers will
be positive for developmental and/or neonatal myosin
labeled regenerating ﬁbers.
Collagen VI Myopathy (COL6-RD): Muscle biopsy
ﬁndings in the COL6-RD are quite variable and depend
on the disease severity and stage. In very young children
and very mildly aﬀected patients there may only be
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disproportion [124]. Later in the disease, myopathic
ﬁndings become more pronounced and dystrophic
features more apparent. Core-like lesions may also be
present [127]. In cases with recessive null mutations, an
overall deﬁciency or absence of collagen VI
immunoﬂuorescence in the muscle will be apparent
(including sarcolemma, endomysium, epimysium and
perimysium), although some may still be seen around
blood vessels. In patients with dominantly acting
mutations, collagen VI immunoreactivity will be absent
from the sarcolemma/basement membrane speciﬁcally,
while there may be no discernible deﬁciency in the
interstitial connective tissue of the endomysium,
epimysium and perimysium [128,129]. For proper
recognition of this phenomenon in particular in partial
deﬁciencies it is necessary to co-label the sarcolemma/
basement membrane with a second basement membrane
antibody (i.e. perlecan, collagen type IV) using two color
double immunoﬂuorescence technique. While many
Bethlem cases also show a recognizable sarcolemmal
speciﬁc deﬁciency, in mild cases in particular in the mild
Bethlem myopathy range, the collagen VI
immunoreactivity in the biopsy may appear normal in
amount and localization. Degenerating and regenerating
ﬁbers are not a prominent feature early on in biopsies
from patients with COL6-RD, however, there may be
ﬁbers present that stain for developmental and/or
neonatal myosin. A sarcolemmal reduction of laminin b1
may be seen in some adult or adolescent cases of Bethlem
myopathy but is not speciﬁc to collagen VI disorders.
Immunohistochemical examination of skin sections (as
opposed to ﬁbroblasts in culture) is only helpful if there
is a complete absence of collagen VI immunoreactivity,
although more recently the application of techniques such
as FACS may allow to appreciate more subtle reduction
in collagen VI expression [88].
SEPN1-RM and RYR1-RM: The muscle pathology
spectrum of SEPN1-RM is broad and includes most but
not all cases of Rigid Spine Muscular Dystrophy
(RSMD1) [130], classic multi-minicore disease [102],
desmin-related myopathy with Mallory body-like
inclusions [131] and in a small percentage of congenital
ﬁber type disproportion (CFTD) cases [105]. Most
SEPN1-RM muscle biopsies show small focal areas of
mitochondria depletion and sarcomere disorganization
(minicores) on oxidative stains in muscle ﬁbers, together
with type 1 ﬁber predominance and variable atrophy,
protein aggregates and/or endomysial ﬁbrosis. Necrosis
and/or regeneration are less frequent but may be present.
There currently is no immunohistochemical diagnostic
stain for SEPN1-RM yet. In RYR1-RM cases presenting
as CMD histological ﬁndings are extremely variable
[111]. Extreme ﬁber atrophy, frequent central nucleation,
ﬁber type uniformity, irregular oxidative enzyme stains
including core-like areas are all features. Overtdegeneration and regeneration is not conspicuous while
fatty-ﬁbrous replacement can be prominent.
LMNA-CMD: The histological appearance of the
muscle biopsy is variable, ranging from a myopathic
appearing biopsy with mostly type 1 atrophic ﬁbers to
more overtly dystrophic ﬁndings, mainly reﬂected as
increased ﬁbrosis and less so by overtly necrotic ﬁbers.
Findings may be diﬀerent between sections in a given
biopsy and between diﬀerent muscles. Conspicuous
cellular inﬁltration suggesting inﬂammation is a feature in
some biopsies and may provide rational for anti-
inﬂammatory steroid therapy [132]. Immunohistochemical
examination for LMNA in the biopsy will be normal as
there is no appreciable deﬁciency or mislocalization of
lamin A/C even in the presence of a mutation causing
severe disease. LMNA-CMD shows no characteristic
protein deﬁciencies by immunohistochemical analysis.
3.8.3. Muscle imaging (ultrasound and magnetic resonance
imaging)
Imaging techniques, such as computed tomography or
resonance magnetic imaging, and ultrasound [133,134]
have assumed increasing importance in the diagnostic
approach for patients with muscle disease and show
speciﬁcity for several genetic entities [62,135–137]. Within
the diagnostic work up of CMDs they have proved to be
particularly useful when suspecting a COL6-RD, SEPN1-
RM, LMNA-CMD and RYR1-CMD [62,138–140]. MRI
should be regarded as a gold standard technique.
Standardized T1 weighted spin echo sequences of the
lower limb, particularly of the thigh muscles are probably
the most informative and should be favored when time
and resources are limited. Whole body MRI has also been
successfully used for the purpose of pattern recognition,
in particular when lower limbs are not speciﬁc enough or
if the myopathy has selective involvement in other parts
of the body [62,141]. The acquisition of images is
generally easy to accomplish in conventional imaging
units. However, the identiﬁcation of a speciﬁc pattern of
muscle involvement requires a high level of expertise and
one should consider sending the images for advice to
international centers of CMD expertise.
In COL6-CMD (Fig. 3G), muscle MRI shows a
characteristic pattern with diﬀuse involvement of fatty
inﬁltration within thigh muscles with relative sparing of
sartorius, gracilis, adductor longus. Localization of fatty
inﬁltration typically takes the form of a rim of
hypodensity at the periphery of muscles particularly in
vasti muscles, with a relative sparing of the central part
indicative of endomysial ﬁbrosis tracking along the
muscle fascia. In the rectus femoris muscle fatty
inﬁltration occurs along the central fascia speciﬁcally
with a centrally located abnormal signal denoted as a
“central shadow sign” on ultrasound [138–140].
In SEPN1-RM (Fig. 3H), selective involvement of
sartorius, semimembranous and great adductor muscles
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diagnosis [142,143]. This pattern may overlap with RYR1
at the thigh level but using WBMRI, selective axial
involvement with striking hypotrophy of neck ﬂexors will
allow diﬀerential diagnosis [62]. A useful imaging based
diﬀerential diagnosis of rigid spine myopathies is
provided by Mercuri et al. [135]. LMNA-RD in
ambulatory patients shows vastus lateralis and
gastrocnemius medialis selective initial involvement. In
the congenital forms with severe weakness, muscle
imaging is informative by regarding the pattern of
relatively spared muscles, (cranial, psoas and forearm
muscles) [141].
Muscle imaging is less used for diagnostic purposes in
the CMD types with central nervous system involvement
or increased CK levels (LAMA2-RD and aDG-RD),
since diagnosis is usually oriented by other
complementary tests (brain MRI, immunohistochemistry).
4. Diagnostic algorithm schematics
The subtype speciﬁc schematics (Supplemental Figs.
A–E) aim to guide the diagnostic workup starting from a
clinical suspicion of CMD with a prioritization of
possible subtype involvement to genetic conﬁrmation of a
CMD diagnosis. Although it is advantageous (less
invasive) and sometimes possible to go directly to genetic
testing for a suspected CMD diagnosis, the algorithms
proposed here favor inclusion of a muscle biopsy
(provided that it can be expertly done, interpreted and
stored). However, given a strong clinical suspicion,
diﬃcult access to quality biopsy services and easier access
to genetic services, a muscle biopsy can sometimes be
skipped. The algorithm can also be used in reverse order
– i.e. when a genetic change is found on panel genetic
testing the algorithm can be followed backwards to assess
whether the gene the mutation was found in is plausible
as a cause of the phenotype in the patient.
5. Final practical considerations and pitfalls
5.1. Interpretation of molecular genetic results
The interpretation of the results of mutation analysis
can be quite straightforward if the pathogenicity of the
mutations is obvious and the mutations are consistent
with the known pattern(s) of inheritance in a given
condition. In the following we address three of the more
likely scenarios and pitfalls that occur in the genetic
conﬁrmation of CMD.
“Missing” second allele: Lack of detection of a second
allele using current methods may occur in particular in
LAMA2-RD, with upwards of 25% of LAMA2-RD
patients having a gene rearrangement (deletion/
duplication of one or more exons) not identiﬁed on
standard Sanger sequencing [20]. Access to quantitative
allele assessment (including MLPA and comparativegenomic array technology) will be important to
appropriately detect this type of mutation in order to
complete the genetic workup. Similar types of genomic
mutations may be found in COL6-RD, however given
the multiple inheritance patterns of COL6-RD one must
carefully evaluate a single variant found on one allele for
its potential to act dominantly before suspecting a
missing allele. Also, in both LAMA2-RD and COL6-RD
cases with only a single allele identiﬁed, there should be
clear diagnostic evidence for the presence of the disease
(such as unequivocal deﬁciency of immunostaining for
laminin a2 or collagen VI in the muscle biopsy) before
suspecting a missing allele.
It is also important to conﬁrm apparent homozygous
mutations by parental analysis. If only one of the parents
carries the mutation it is possible that the patient is in fact
hemizygous for the initially detected mutation because of
the presence of a larger deletion on the other allele. Other
important possibilities for a “missing” second allele are
mutations in regulatory regions of the gene as well as
deep intronic mutations that could inﬂuence splicing but
elude mutation analysis based on exonic sequencing
alone. In such situations research laboratory based
analysis of cDNA from muscle or from dermal ﬁbroblast
cultures (for COL6-RD, aDG-RD, SEPN1-RM and
LMNA-CMD analysis) can be helpful to detect additional
deep intronic mutations that may aﬀect splicing of exons.
In SEPN1 it is important to not forget to include the
SECIS sequence located in the 30UTR [107].
Recognizing dominantly acting mutations: Autosomal
dominant mutations are required to be co-inherited with the
phenotype in families with a positive family history, or
conﬁrmed as dominant “sporadic” and de novo conﬁrmed
by parental testing. The possibility of somatic and germline
mosaicisim in dominant de novo mutations should always
be considered and has been reported in LMNA-CMD and
COL6-RM, with obvious implications on genetic
counseling. All hitherto recognized LMNA-CMD
mutations are dominantly acting. In COL6-RD, mutations
acting in a dominant fashion are common in Ullrich,
intermediate and Bethlem phenotypes, but recessive
mutations can also cause all three phenotypes. For
accurate genetic counseling and disease recurrence risk for
family planning it is thus essential to decide whether a
single detected mutation would be expected to act in a
dominant manner, or whether only one of two recessive
mutations has been detected (missing allele). Clearly
dominantly acting mutations have been identiﬁed as such
with solid supporting evidence and are usually annotated
in genetic reports. Genomic deletions and deep intronic
mutations may also lead to dominantly acting exon
skipping (see earlier discussion for COL6-RD). Missense
mutations elsewhere in the collagen VI genes that have not
been previously convincingly reported as pathogenic are
much harder to interpret and one cannot automatically
assume the mechanism of its action and counsel for
recurrence risk.
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(Variant of Unknown Signiﬁcance, VOUS): To reduce the
chance of having to deal with sequence changes of
unclear signiﬁcance it is best to focus the sequence
analysis on the gene(s) that is most likely to be
responsible for the disease phenotype in the patient, using
clinical and paraclinical analysis outlined above.
Undirected shot-gun approaches to genetic testing, as in
parallel sequencing array platforms and whole exome or
genome sequencing will result in a number of VOUS
potentially confusing genetic conﬁrmation for the
individual patient. Testing parents for the variant is
important to establish whether the change follows the
pattern of inheritance predicted for a mutation in the
suspected CMD subtype, including de novo occurrence in
the patient or co-inheritance with the disease from an
aﬀected parent for forms with a possible dominant
mechanism (COL6-RD, LMNA-CMD). Finding a single
variant initially detected in both a sporadic patient and in
unaﬀected family members suggests a benign sequence
variant under consideration of a dominant mechanism,
or, under consideration of a recessive mechanism, that
the required other allele has not been detected. Literature
review to identify additional publications describing the
variant in question and in silico analysis should be
performed by the testing laboratory to determine the
presumed variant’s eﬀect based upon the secondary
protein structure and degree of evolutionary conservation
of the aﬀected amino acid. An innocent appearing
missense mutation or even a synonymous change (a
mutation that does not change an amino acid) could still
be pathogenic by interfering with an exonic splice
enhancer, thereby leading to exon skipping. In silico
analysis can also be performed for this type of change
but is imperfect at such predictions. However, cDNA
analysis in muscle or in ﬁbroblast culture may provide a
direct answer by conﬁrming the presence or absence of
an abnormal splicing event. Helpful ancillary
investigations may include additional stainings on the
muscle biopsy, and dermal ﬁbroblast analysis to assess
collagen VI matrix formation in the case of COL6-RD.
For the aDG-RDs, ﬁbroblasts or lymphoblasts [144] can
be used for direct assays of enzymatic activity for
POMT1, POMT2 and POMTGnT1. It is also possible to
assess ﬁbroblast aDG glycosylation and perform
complementation assays directed at pinpointing the
defective gene in selected situations [64,68].
It is equally important to keep track of patients with
convincing clinical and paraclinical phenotypes but
without genetic conﬁrmation (i.e. mutation analysis was
performed but was negative or inconclusive) as new genes
can be expected to be discovered in the future, eventually
allowing for a diagnosis in such patients.
Massive parallel sequencing of groups of disease genes
and whole exome sequencing as the primary diagnostic
tool: Next generation based sequencing will be
increasingly available in the diagnosis of the CMDs [145].This can take the form of targeted massively parallel re-
sequencing of groups of disease implicated genes, or be
based of whole exome sequencing. These technologies can
be very beneﬁcial in that they can lead eﬃciently and
directly to the genetic diagnosis, provided the mutation
found are clear and unequivocal. Even in those situations
it is mandatory to compare the sequencing results with
the ascertained clinical and morphological phenotype as
outlined here to make sure the genetic and clinical results
are congruent. A more challenging situation arises if
potentially pathogenic variants are detected in more than
one relevant disease gene, a relatively common
occurrence. In these scenarios it will be very helpful to
carefully follow the algorithms outlined here to arrive at
the most likely genetic diagnosis from a clinical point of
view. With clinical direction it will be considerably easier
to weigh the changes found on next generation
sequencing. Finally, if the clinical analysis strongly
suggests a speciﬁc diagnosis that is not reﬂected in the
results obtained from next generation sequencing it is
important to interrogate the genetic platform used for
types of mutation that could have been missed because of
poor coverage of certain exons, insensitivity to larger
deletions and genomic rearrangements and lack of
detection of deep intronic changes. A careful clinically
informed approach to the diagnosis of the CMDs thus
will not become obsolete but only gain in importance in
conjunction with the application of next generation
genetic technology.
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